T674I FIP1L1-PDGFRα, analogous to T315I Bcr-Abl in CML, is also resistant to the second-generation TKIs, such as nilotinib [8]. This evidence concerns the gene FIP1L1 and chronic myelogenous leukemia, BCR-ABL1 positive.